NCT06005792View on ClinicalTrials.gov

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
PsoriasisAtopic Dermatitis
Interventions
BIOLOGICAL

XmAb27564

Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).

BIOLOGICAL

Placebo

Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).

Trial Locations (7)

33104

San Marcus Research Clinic, Miami Lakes

33134

Driven Research, Coral Gables

77598

Center for Clinical Studies, LTD. LLP, Webster

77845

J&S Studies, Inc, College Station

91320

Clinical Trials Research Institute, Thousand Oaks

91403

Unison Clinical Trials, Sherman Oaks

H2X 2V1

Innovaderm Research Inc., Montreal

All Listed Sponsors
lead

Xencor, Inc.

INDUSTRY